Joseph Carson
…Paul Jones, former FDA official and Executive Vice President of Ketryx, provide an overview of challenges companies face as they work to comply with the new cybersecurity regulations and standards….
…Paul Jones, former FDA official and Executive Vice President of Ketryx, provide an overview of challenges companies face as they work to comply with the new cybersecurity regulations and standards….
…cybersecurity management plans that communicate how they will identify and communicate postmarket vulnerabilities in accordance with 21 CFR 820.100. Recommends that manufacturers provide an updateability and patchability view that describes…
…cybersecurity management plans that communicate how they will identify and communicate postmarket vulnerabilities in accordance with 21 CFR 820.100. Recommends that manufacturers provide an updateability and patchability view that describes…
Cough is a common and, at times, problematic medical condition that is ripe for disruption. It is one of the main reasons why patients seek medical care. In Europe and…
Cough is a common and, at times, problematic medical condition that is ripe for disruption. It is one of the main reasons why patients seek medical care. In Europe and…
…new drug advancing to the next trial stage or regulatory approval is less than 14% across all therapeutic areas. These high failure rates are often attributed to the tremendous amount…
…new drug advancing to the next trial stage or regulatory approval is less than 14% across all therapeutic areas. These high failure rates are often attributed to the tremendous amount…
…device resulting in harm to a user or patient. Subscribe to the MedTech Intelligence weekly newsletter to stay up to date on the latest news and information on medical device…
…device resulting in harm to a user or patient. Subscribe to the MedTech Intelligence weekly newsletter to stay up to date on the latest news and information on medical device…